Crossmark

Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis

Published Online: 2024-10-01

Authors

Girard, Andrew A.

Sperry, Brett W.
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-01
More Information

Article History

Accepted: 26 September 2024

First Online: 1 October 2024

Declarations

:

: BWS consults for Alnylam, BridgeBio, AstraZeneca and is a speaker for Pfizer and AstraZeneca.

Document is current